Amlitelimab

• CAT Number: I042347
• Purity: ≥95%

Amlitelimab (Cat No.: I042347) is a human monoclonal antibody targeting OX40 ligand (OX40L), a key costimulatory molecule involved in T-cell activation and inflammatory responses. By blocking the interaction between OX40L and its receptor OX40, amlitelimab modulates immune activity, aiming to reduce chronic inflammation. It is being investigated for the treatment of immune-mediated conditions such as atopic dermatitis and other autoimmune diseases. Amlitelimab offers a novel, upstream approach to immune regulation, potentially providing long-lasting therapeutic effects with fewer systemic side effects compared to conventional immunosuppressants.

Reference

[1]. Ana Maria Lé, et al. OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. Pharmaceutics 2022, 14(12), 2753.

[2]. Saghari M, et al. OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005. Clin Pharmacol Ther. 2022 May;111(5):1121-1132.
[Content Brief]

[3]. Tkachev V, et al. Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant. Sci Transl Med. 2017 Sep 20;9(408):eaan3085.
[Content Brief]